Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Tidal Investments LLC

Tidal Investments LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,350 shares of the biopharmaceutical company’s stock after purchasing an additional 510 shares during the period. Tidal Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $6,675,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 6.5% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 1,692 shares of the biopharmaceutical company’s stock worth $1,778,000 after purchasing an additional 104 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 316.2% in the 2nd quarter. Blue Trust Inc. now owns 283 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 215 shares during the period. Hoylecohen LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $222,000. OFI Invest Asset Management boosted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the second quarter. OFI Invest Asset Management now owns 1,226 shares of the biopharmaceutical company’s stock worth $1,202,000 after buying an additional 26 shares during the last quarter. Finally, Raymond James & Associates grew its holdings in Regeneron Pharmaceuticals by 4.0% during the second quarter. Raymond James & Associates now owns 74,228 shares of the biopharmaceutical company’s stock worth $78,016,000 after acquiring an additional 2,887 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Citigroup started coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective on the stock. Bank of America reissued an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.90.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $731.30 on Friday. The company has a market cap of $80.36 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.32 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $728.68 and a twelve month high of $1,211.20. The company’s 50-day moving average price is $849.77 and its 200-day moving average price is $1,003.80. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.